KRISTEN MARRONE

Allopathic & Osteopathic Physicians|Internal Medicine BALTIMORE, MD NPI 1780973271

General Payments — all program years on this page

$99,116.36

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 76
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $17,553.63 across 17 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $15,758.005
Food and Beverage $1,183.5010
Travel and Lodging $612.132

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Daiichi Sankyo Inc. $6,981.102
Regeneron Pharmaceuticals, Inc. $6,065.0812
E.R. Squibb & Sons, L.L.C. $2,400.001
AstraZeneca UK Limited $1,995.001
Acerta Pharma LLC $112.451

By program year

Program yearAmountRecords
2018 $5,820.178
2019 $1,863.0211
2020 $7,681.505
2021 $18,287.505
2022 $12,130.916
2023 $35,779.6324
2024 $17,553.6317

Records — PY2024 (17)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1089452620 Daiichi Sankyo Inc. $231.10 01/22/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1089452622 Daiichi Sankyo Inc. $6,750.00 01/24/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093891782 AstraZeneca UK Limited $1,995.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1101637026 E.R. Squibb & Sons, L.L.C. $2,400.00 12/13/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1104309256 AstraZeneca Pharmaceuticals LP $112.45 11/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114402427 Regeneron Pharmaceuticals, Inc. $100.45 02/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114402429 Regeneron Pharmaceuticals, Inc. $1,318.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1114402431 Regeneron Pharmaceuticals, Inc. $3,295.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1114402433 Regeneron Pharmaceuticals, Inc. $381.03 08/01/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114402435 Regeneron Pharmaceuticals, Inc. $141.08 08/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114402437 Regeneron Pharmaceuticals, Inc. $153.50 08/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114402439 Regeneron Pharmaceuticals, Inc. $105.45 08/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114402441 Regeneron Pharmaceuticals, Inc. $148.04 08/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114402443 Regeneron Pharmaceuticals, Inc. $150.01 08/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114402445 Regeneron Pharmaceuticals, Inc. $113.59 08/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114402447 Regeneron Pharmaceuticals, Inc. $64.27 08/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114402449 Regeneron Pharmaceuticals, Inc. $94.66 08/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.